Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Published on 31/07/202504/08/2025 by Top Pharmaceutical

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile

Scopus

Education

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.

Prof Dr. Ali Shayanfar|Pharmaceutical Chemistry |Best Researcher Award

Published on 30/08/202430/08/2024 by Top Pharmaceutical

Prof Dr. Ali Shayanfar|Pharmaceutical Chemistry |Best Researcher Award|

Prof Dr. Ali Shayanfar at abriz University of Medical Sciences, Iran

PROFILE

Google scholar

Early Academic Pursuits 🎓

Shayan Fara began his academic journey at the Faculty of Pharmacy, Tabriz University of Medical Sciences, where he earned his Pharm.D. from 2003 to 2009. During these formative years, he developed a strong foundation in pharmaceutical sciences, laying the groundwork for his future career. His passion for pharmaceutical chemistry drove him to pursue a Ph.D. in the same field at Tabriz University of Medical Sciences from 2009 to 2013. His doctoral research focused on the solid-state and solution chemistry of drugs, an area that would later become a central theme of his research.

Professional Endeavors and Career Growth 🏢

After completing his Ph.D., Dr. Fara joined the Faculty of Pharmacy at Tabriz University of Medical Sciences as an Assistant Professor of Pharmaceutical Chemistry in 2014. His dedication to teaching and research led to a steady rise in his academic career. By 2018, he had been promoted to Associate Professor, and in 2023, he reached the pinnacle of his academic career by becoming a full Professor of Pharmaceutical Chemistry.

Dr. Fara’s professional endeavors extend beyond teaching. He has held several key administrative positions, including serving as the Secretary and Research Secretary of the Student Research Committee at Tabriz University of Medical Sciences. His leadership skills and commitment to research were further recognized when he became the Head of the Student Research Committee from 2018 to 2020.

Contributions and Research Focus 🧪

Dr. Fara’s research interests are diverse and impactful, focusing on the solid-state and solution chemistry of drugs, pharmaceutical and biomedical analysis, and modeling in pharmaceutical sciences. He has made significant contributions to understanding the physical and chemical properties of drugs in both solid and solution states. His work in this area has implications for drug formulation, stability, and bioavailability, making it crucial for the development of more effective pharmaceutical products.

His expertise extends to various analytical techniques, including UV-Vis spectrophotometry, HPLC, spectrofluorimetry, FT-IR, DSC, and PXRD. He has also conducted extensive research in chemometrics, molecular modeling, QSAR and QSPR studies, solubility and dissolution rate determination techniques, and crystallization of drugs. His technical prowess in these areas has enabled him to contribute to the advancement of pharmaceutical sciences, both in theory and practice.

Accolades and Recognition 🏆

Throughout his career, Dr. Fara has received numerous accolades and recognition for his contributions to pharmaceutical sciences. His role as an editor in several prestigious journals, including being the Editor-in-Chief of the Pharmaceutical Sciences Journal since 2020, highlights his influence in the field. He has also served as an Associate Editor for the Pharmaceutical Sciences Journal from 2014 to 2020 and for the Directory of Open Access Journals (DOAJ) from 2017 to 2018.

His editorial roles, combined with his contributions to research, have earned him a place on the editorial boards of several high-impact journals, including Pharmaceutical Sciences and ImmunoAnalysis. His involvement with these journals not only showcases his expertise but also his commitment to advancing the quality and accessibility of scientific knowledge.

Impact and Influence 🌍

Dr. Fara’s impact on the field of pharmaceutical sciences is profound. His research has influenced the development of new analytical methods and drug formulations, contributing to the broader field of pharmaceutical chemistry. His work in modeling and chemometrics has provided valuable insights into the relationship between drug properties and their therapeutic efficacy.

In addition to his research contributions, Dr. Fara has been instrumental in mentoring the next generation of pharmaceutical scientists. His teaching experience spans various subjects, including Analytical Chemistry, Medicinal Chemistry, Instrumental Analysis, General Chemistry, Medical Information Systems, Research Methods, Endnote Software, and Ethics in Publication. His dedication to education ensures that his influence will extend far beyond his direct contributions to research.

Legacy and Future Contributions 🌟

As Dr. Fara continues his career as a Professor of Pharmaceutical Chemistry, his legacy is already being built through his research, teaching, and editorial work. His ongoing contributions to the field, particularly in the areas of drug analysis and modeling, will continue to shape the future of pharmaceutical sciences. His commitment to excellence in research and education, combined with his leadership in various academic and editorial roles, ensures that his impact will be felt for years to come.

🎓Publication

Solubility of carvedilol in ethanol+ propylene glycol mixtures at various temperatures

Authors :Sahel Vahdati, Ali Shayanfar, Jalal Hanaee, Fleming Martínez, William E Acree Jr, Abolghasem JouybanA et al...

Journal :Industrial & Engineering Chemistry Research
Year :2013

Review of pharmaceutical applications of N-methyl-2-pyrrolidone

Authors :Abolghasem Jouyban, Mohammad Amin Abolghasemi Fakhree, Ali Shayanfar

Journal :Journal of Pharmacy & Pharmaceutical Sciences
Year :2010

Deep eutectic solvents for pharmaceutical formulation and drug delivery applications

Authors :Shahram Emami, Ali Shayanfar

Journal :Pharmaceutical development and technology
Year :2020

Effect of choline chloride/ethylene glycol or glycerol as deep eutectic solvents on the solubility and thermodynamic properties of acetaminophen

Authors : Hemayat Shekaari, Mohammed Taghi Zafarani-Moattar, Ali Shayanfar, Masumeh Mokhtarpour

Journal :Journal of Molecular Liquids
Year :2018

Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy

Authors :Ommoleila Molavi, Farzaneh Narimani, Farshid Asiaee, Simin Sharifi, Vahideh Tarhriz, Ali Shayanfar, Mohammadsaied Hejazi, Raymond Lai

Journal : Pharmaceutical biology
Year :2017